| Intrinsic Valuation of: TORNTPHARM | |||||||||||
| Free Cash Flow Average and Growth over past 5Y | Key Statistics | ||||||||||
| Year | FCF | FCF (FCF/Revenue) | |||||||||
| 2020 | - | - | EPS (FY) | 57 | Market Cap | ₹1,156B | |||||
| 2021 | - | - (-) | P/E Ratio | 60 | Total Asset | ₹150B | |||||
| 2022 | ₹16B | - (-) | Net Income | ₹19B | Total Debt | ₹12B | |||||
| 2023 | ₹18B | 12.1% (-0.3%) | EBITDA | ₹37B | Total Liab | ₹74B | |||||
| 2024 | ₹28B | 57.9% (41.5%) | Opr Margin | 0.26 | Debt/Equity | 0.16 | |||||
| 2025 | ₹20B | -30.3% (-35.0%) | PreTax Margin | 23.63 | BV/Share | 88 | |||||
| 5Y Average FCF | ₹21B | 13.2% (2.1%) | |||||||||
| Overall Market Assumptions: | |||||||||||
| Assumptions: | P/E for No-Growth Company: | 7.0 | |||||||||
| Perpetual Growth Rate (g): | 2.5% | Historical US Bond Yield: | 4.4% | ||||||||
| Discount Rate (WACC): | 7.4% | Current US Bond Yield: | 3.5% | ||||||||
| Forcasting Future Free Cash Flow for next 6Y | Modified Benjamin Graham's Intrinsic Value | ||||||||||
| Year | FCF Projection (13.2%) | ||||||||||
| 2026 | ₹22B | MBG Intrinsic Value | ₹507 | ||||||||
| 2027 | ₹25B | ||||||||||
| 2028 | ₹29B | ||||||||||
| 2029 | ₹32B | ||||||||||
| 2030 | ₹37B | ||||||||||
| 2031 | ₹42B | ||||||||||
| Terminal Value | ₹865B | Net Worth/Share | ₹224 | ||||||||
| DCF Valuation | DCF Valuation "What If" Scenario Table | ||||||||||
| Enterprise Value | ₹706B | Growth Rate | |||||||||
| (+) Cash & Cash Equivalents | ₹6B | ₹2,066 | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | ||||
| (-) Total Debt | ₹12B | WACC | 7.3% | 1,805 | 1,944 | 2,112 | 2,318 | 2,578 | |||
| Equity Value | ₹699B | 7.4% | 1,789 | 1,925 | 2,089 | 2,290 | 2,544 | ||||
| Shares Outstanding | 338,444,992 | 7.4% | 1,773 | 1,906 | 2,066 | 2,263 | 2,510 | ||||
| 7.9% | 1,624 | 1,734 | 1,865 | 2,021 | 2,214 | ||||||
| DCF Intrinsic Value | ₹2,066 | 8.4% | 1,498 | 1,590 | 1,697 | 1,825 | 1,978 | ||||
| Analyzed by QuantJuice (2025) | |||||||||||